These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21900191)

  • 1. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.
    Zimran A; Brill-Almon E; Chertkoff R; Petakov M; Blanco-Favela F; Muñoz ET; Solorio-Meza SE; Amato D; Duran G; Giona F; Heitner R; Rosenbaum H; Giraldo P; Mehta A; Park G; Phillips M; Elstein D; Altarescu G; Szleifer M; Hashmueli S; Aviezer D
    Blood; 2011 Nov; 118(22):5767-73. PubMed ID: 21900191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
    Zimran A; Durán G; Giraldo P; Rosenbaum H; Giona F; Petakov M; Terreros Muñoz E; Solorio-Meza SE; Cooper PA; Varughese S; Alon S; Chertkoff R
    Blood Cells Mol Dis; 2019 Sep; 78():14-21. PubMed ID: 27499018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
    Zimran A; Wajnrajch M; Hernandez B; Pastores GM
    Orphanet J Rare Dis; 2018 Feb; 13(1):36. PubMed ID: 29471850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
    Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
    Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Elstein D; Paz A; Brill-Almon E; Chertkoff R
    Blood Cells Mol Dis; 2015 Jan; 54(1):9-16. PubMed ID: 25453586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
    Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
    Zimran A; Durán G; Mehta A; Giraldo P; Rosenbaum H; Giona F; Amato DJ; Petakov M; Muñoz ET; Solorio-Meza SE; Cooper PA; Varughese S; Chertkoff R; Brill-Almon E
    Am J Hematol; 2016 Jul; 91(7):656-60. PubMed ID: 27174694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
    Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
    Kuter DJ; Wajnrajch M; Hernandez B; Wang R; Chertkoff R; Zimran A
    Blood Cells Mol Dis; 2020 May; 82():102418. PubMed ID: 32146279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease.
    van Dussen L; Zimran A; Akkerman EM; Aerts JM; Petakov M; Elstein D; Rosenbaum H; Aviezer D; Brill-Almon E; Chertkoff R; Maas M; Hollak CE
    Blood Cells Mol Dis; 2013 Mar; 50(3):206-11. PubMed ID: 23199589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
    Abbas R; Park G; Damle B; Chertkoff R; Alon S
    PLoS One; 2015; 10(6):e0128986. PubMed ID: 26053270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
    Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
    Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
    Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
    Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
    Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
    Grabowski GA; Golembo M; Shaaltiel Y
    Mol Genet Metab; 2014 May; 112(1):1-8. PubMed ID: 24630271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS).
    Titievsky L; Schuster T; Wang R; Younus M; Palladino A; Quazi K; Wajnrajch MP; Hernandez B; Becker PS; Weinreb NJ; Chambers C; Mansfield R; Taylor L; Tseng LJ; Kaplan P
    Orphanet J Rare Dis; 2022 Apr; 17(1):145. PubMed ID: 35365177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease.
    Hollak CE
    Core Evid; 2012; 7():15-20. PubMed ID: 22654679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
    Zimran A; Pastores GM; Tylki-Szymanska A; Hughes DA; Elstein D; Mardach R; Eng C; Smith L; Heisel-Kurth M; Charrow J; Harmatz P; Fernhoff P; Rhead W; Longo N; Giraldo P; Ruiz JA; Zahrieh D; Crombez E; Grabowski GA
    Am J Hematol; 2013 Mar; 88(3):172-8. PubMed ID: 23339116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.